Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD72F4)

Drug Name
T-817MA Drug Info
Synonyms
Edonerpic maleate; T-817MA; UNII-0LB9F7I5P3; 0LB9F7I5P3; 519187-97-4; T-817; T-817 maleate; SCHEMBL48064; RLUCYBFCLXANSO-BTJKTKAUSA-N; HY-17631A; DC10762; CS-8069; J2.179.155E; 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol maleate; 1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate; 1-(3-(2-(Benzo(b)thiophene-5-yl)ethoxy)propyl)azetidine-3-ol maleate; 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)-3-azetidinol maleate; 3-Azetidinol, 1-(3-(2-benzo(b)thien-5-ylethoxy)propyl)-, (2Z)-2-butenedioate (1:
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 2 [1]
Cross-matching ID
PubChem CID
11338749
CAS Number
CAS 519187-97-4
TTD Drug ID
DMD72F4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Lipid peroxidation (LPO)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RAXOFELAST DMK2E0N Ischemia 8B10-8B11 Phase 2 [4]
TAK-218 DM7S69Q Neurological disorder 6B60 Discontinued in Phase 2 [5]
U-104067F DMC94D2 Neurological disorder 6B60 Discontinued in Phase 1 [6]
G009 DMXZGKI Immune System disease 4A01-4B41 Investigative [7]
Drug(s) Targeting Amyloid beta A4 protein (APP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nirogacestat DMUP5Z0 Desmoid tumour 2F7C Approved [8]
Aducanumab DM51JW4 Alzheimer disease 8A20 Approved [9]
Lecanemab DMW03YD Alzheimer disease 8A20 Approved [10]
Florbetapir F-18 DMJ8A3Z Diagnostic imaging N.A. Approved [11]
GV-971 DMTMA5W Alzheimer disease 8A20 Approved in China [12]
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [13]
Solanezumab DM0HIU5 Alzheimer disease 8A20 Phase 3 [14]
Tramiprosate DM7BSRH Alzheimer disease 8A20 Phase 3 [15]
Bapineuzumab DMHQ5GK Alzheimer disease 8A20 Phase 3 [16]
ALZT-OP1 DMG5BTD Alzheimer disease 8A20 Phase 3 [17]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Amyloid beta A4 protein (APP) TTE4KHA A4_HUMAN Inhibitor [2]
Lipid peroxidation (LPO) TTV0YFR NOUNIPROTAC Modulator [3]

References

1 ClinicalTrials.gov (NCT02079909) Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Neuropharmacology. 2008 Oct;55(5):654-60.
4 Lipid peroxidation inhibition by raxofelast improves angiogenesis and wound healing in experimental burn wounds. Shock. 2005 Jul;24(1):85-91.
5 ESR study on the antioxidant activity of TAK-218 in biological model membranes. Chem Pharm Bull (Tokyo). 2000 Jun;48(6):784-92.
6 Two novel pyrrolopyrimidine lipid peroxidation inhibitors U-101033E and U-104067F protect facial motor neurons following neonatal axotomy. Exp Neurol. 1996 Oct;141(2):304-9.
7 Inhibition of lipid peroxidation and oxidative DNA damage by Ganoderma lucidum. Phytother Res. 2001 May;15(3):245-9.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18.
10 The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
12 Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019 Oct;29(10):787-803.
13 Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9.
14 Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21.
15 Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47.
16 Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82.
17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)